Sagittarius Life Science Corp (TPEX:3205)
Taiwan · Delayed Price · Currency is TWD 62.10
+0.20 (0.32%)
Apr 17, 2026, 1:30 PM CST
Sagittarius Life Science Revenue
In the year 2025, Sagittarius Life Science had annual revenue of 346.08M TWD, down -26.01%. Sagittarius Life Science had revenue of 39.57M in the quarter ending December 31, 2025, a decrease of -66.45%.
Revenue
346.08M
Revenue Growth
-26.01%
P/S Ratio
12.12
Revenue / Employee
3.09M
Employees
112
Market Cap
4.19B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 346.08M | -121.67M | -26.01% |
| Dec 31, 2024 | 467.75M | 27.29M | 6.20% |
| Dec 31, 2023 | 440.46M | -88.61M | -16.75% |
| Dec 31, 2022 | 529.07M | -58.55M | -9.96% |
| Dec 31, 2021 | 587.61M | 29.43M | 5.27% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Medigen Biotechnology | 1.58B |
| Genovate Biotechnology | 492.41M |
| BioGend Therapeutics | 222.34M |
| Pharmosa Biopharm | 67.27M |
| OBI Pharma | 58.58M |
| ACRO Biomedical | 36.50M |
| UnicoCell Biomed | 30.10M |
| Shine-On BioMedical | 30.00M |